Scilex Holding Company (SCLX) - News Archive

Scilex Holding Company Addresses Product Composition Questions for ELYXYB Patent in Canada, While Preparing for the Launch of Gloperba and Expanding Its Distribution NetworkPALO ALTO, Calif., March 18, 2024 Scilex Holdi...

Scilex Holding Company, a renowned player in the non-opioid pain management sector, has recently achieved a significant milestone by obtaining the highly esteemed Halal Certification for its commercial product, ZTlido....

In a groundbreaking move, Scilex Holding Company, a leading provider of non-opioid pain management solutions, has closed a highly successful $10 million bought deal offering. The innovative revenue-generating company, f...

Scilex Holding Company Announces Launch of Gloperba, the First Liquid Colchicine for Painful Gout Flares, Priced at $595 per BottleIn an exciting development for gout sufferers, Scilex Holding Company has announced plan...

In a recent press release, Scilex Holding Company announced a significant milestone in its journey towards advancing non-opioid pain management products. The company has entered into an underwriting agreement with Rodma...

Scilex Holding Company Partners with National Pharmacy Chain to Bring GLOPERBA to Wider Market PALO ALTO, Calif., Feb. 28, 2024 - Scilex Holding Company (Nasdaq: SCLX, Scilex or Company) has announced a groundbreaking p...

:Scilex Holding Company (Scilex), a revenue-generating pharmaceutical company specializing in non-opioid pain management products, has announced the acceptance of an abstract for poster and oral presentation at the 2024...

In an exciting development, Scilex Holding Company, a leading pioneer in non-opioid pain management solutions, has recently published the results of an investigator-initiated research study in the esteemed Anesthesiolog...

In a recent letter addressed to stockholders, Jaisim Shah, CEO and President of Scilex Holding Company, highlighted the significant accomplishments of the company in 2023 and provided a positive outlook for the upcoming...

Palo Alto, Calif., December 15, 2023 Scilex Holding Company (Nasdaq: SCLX, Scilex, or the Company), a trailblazer in the medical industry whose primary focus lies in the acquisition, development, and commercialization o...

Scilex Holding Company, a leading player in the non-opioid pain management industry, has taken a significant step towards expanding access to its flagship product, ELYXYB. In a recent announcement, Scilex revealed that...

Scilex Holding Company s ZTlido Added as Preferred Agent to Tennessee s Medicaid Drug List, Enhancing Patient AccessScilex Holding Company, a leading player in non-opioid pain management products, has recently announced...

Scilex Holding Company, a leading player in non-opioid pain management products, recently achieved a significant milestone in its operations. The company announced the successful completion of a Good Manufacturing Pract...

IntroductionIn a significant move towards revolutionizing non-opioid pain management, Scilex Holding Company has recently announced its pharmacy initiative to stock ELYXYB in over 500 stores of a leading pharmacy chain...

Scilex Holding Company Set to Launch FDA-Approved Gloperba in the U.S. in Q1 2024In an exciting development, Scilex Holding Company has announced the completion of commercial manufacturing of their groundbreaking produc...

Scilex Holding Company, a prominent player in the acquisition and development of non-opioid pain management products, has disclosed the results of an insightful market research study. The study unveils the potential of...

In a recent press release, Scilex Holding Company, a renowned innovator in the field of non-opioid pain management products, has made an important announcement regarding the short positions on restricted shares of Scile...